Home
Pharma News
CDM
Clinical Research
Medical Writing
Regulatory Affairs
More
Clinical coding (Medical)
Clinical Research Associate
Centralized Monitoring
HEOR (Health Economics and Outcome Research)
Pharmacovigilanc​e
Scientific Writing
Other
About us
Search
CLINSQUARE: CLINICAL RESEARCH COURSES
Saturday, May 4, 2024
Home
Pharma News
CDM
Clinical Research
Medical Writing
Regulatory Affairs
More
Clinical coding (Medical)
Clinical Research Associate
Centralized Monitoring
HEOR (Health Economics and Outcome Research)
Pharmacovigilanc​e
Scientific Writing
Other
About us
Facebook
Twitter
CLINSQUARE: Clinical Rsearch Courses by LIFEPRONOW
Home
Pharma News
CDM
Clinical Research
Medical Writing
Regulatory Affairs
More
Clinical coding (Medical)
Clinical Research Associate
Centralized Monitoring
HEOR (Health Economics and Outcome Research)
Pharmacovigilanc​e
Scientific Writing
Other
About us
Search
Home
Latest Pharma-News
Latest Pharma-News
Latest Pharma-News
FDA Takes Steps to Ensure Safety of Cinnamon Products Sold in the US
admin
-
March 8, 2024
Latest Pharma-News
FDA Clears First Over-the-Counter Continuous Glucose Monitor
admin
-
March 8, 2024
Latest Pharma-News
FDA, Industry Actions End Sales of PFAS Used in US Food Packaging
admin
-
March 1, 2024
Latest Pharma-News
Regulatory Applications Accepted in the U.S. and Japan for BMS Breyanzi in Relapsed or Refractory FL and Relapsed or Refractory MCL
admin
-
February 3, 2024
Latest Pharma-News
BlueRock Therapeutics exercises exclusive option to license iPSC cell therapy candidate OpCT-001 for Primary Photoreceptor Diseases
admin
-
February 1, 2024
Latest Pharma-News
FDA Approves Medtronic Micra™ AV, the World’s Smallest Pacemaker with atrioventricular (AV) synchrony for the treatment of patients with AV block
admin
-
January 24, 2020
0
Latest Pharma-News
Akcea and Ionis report positive topline Phase 2 results of AKCEA-APOCIII-L Rx for the treatment of hypertriglyceridemia
admin
-
January 24, 2020
0
Latest Pharma-News
European Commission approves Darzalex® in combination with bortezomib, thalidomide and dexamethasone for multiple myeloma
admin
-
January 23, 2020
0
Latest Pharma-News
Jazz Pharmaceuticals reported that EU Marketing Authorisation for Sunosi® (solriamfetol) for Excessive Daytime Sleepiness in Adults with Narcolepsy or Obstructive Sleep Apnea
admin
-
January 23, 2020
0
Latest Pharma-News
AstraZeneca’s ‘Desire Zero Carbon’ system to take out outflows by 2025 and be carbon negative over the whole worth chain by 2030
admin
-
January 23, 2020
0
Latest Pharma-News
Free “LabXchange” Science Education Accelerator Launched By the Amgen Foundation And Faculty of Arts and Sciences at Harvard
admin
-
January 23, 2020
0
Latest Pharma-News
US FDA grants priority review of GlaxoSmithKline’s belantamab mafodotin for patients with relapsed or refractory multiple myeloma
admin
-
January 22, 2020
0
Latest Pharma-News
The U.S.FDA approved Horizon Therapeutics Tepezza (teprotumumab-trbw) for the treatment of adults with thyroid eye disease
admin
-
January 22, 2020
0
Latest Pharma-News
Supernus Announces U.S. FDA Acceptance for Review of the New Drug Application for SPN-812 for the Treatment of ADHD
admin
-
January 22, 2020
0
Latest Pharma-News
The European Commission (EC) approved Novartis Mayzent® (siponimod) for adult patients with secondary progressive multiple sclerosis (SPMS) with active disease
admin
-
January 22, 2020
0
Latest Pharma-News
AstraZeneca’s Imfinzi and tremelimumab granted Orphan Drug Designation in the US for the treatment of hepatocellular carcinoma
admin
-
January 21, 2020
0
Latest Pharma-News
Heroic-Faith Medical Science expects US FDA clearance for AI-powered respiratory monitor
admin
-
January 20, 2020
0
1
...
131
132
133
...
144
Page 132 of 144
- Advertisment -
Most Read
FDA Takes Steps to Ensure Safety of Cinnamon Products Sold in the US
March 8, 2024
FDA Clears First Over-the-Counter Continuous Glucose Monitor
March 8, 2024
FDA, Industry Actions End Sales of PFAS Used in US Food Packaging
March 1, 2024
Regulatory Applications Accepted in the U.S. and Japan for BMS Breyanzi in Relapsed or Refractory FL and Relapsed or Refractory MCL
February 3, 2024